HCW Biologics Inc. (NASDAQ:HCWB – Get Free Report) rose 0.3% during trading on Thursday . The company traded as high as $0.41 and last traded at $0.39. Approximately 290,430 shares traded hands during trading, a decline of 97% from the average daily volume of 11,194,245 shares. The stock had previously closed at $0.39.
HCW Biologics Trading Down 0.3 %
The stock has a market capitalization of $17.37 million, a P/E ratio of -0.39 and a beta of 0.81. The stock’s 50 day simple moving average is $0.39 and its 200 day simple moving average is $0.47.
About HCW Biologics
HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.
See Also
- Five stocks we like better than HCW Biologics
- What is an Earnings Surprise?
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- What Are Dividend Champions? How to Invest in the Champions
- DuPont’s Electronics Spinoff: The Start of Something Big
- Consumer Discretionary Stocks Explained
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
